By the end, Jayme Strauss’s father-in-law could not tell his grandchildren he loved them, though, as she puts it, he was “still fully there”. Strauss is now chief clinical officer at Precision Neuroscience, and on 13 November the New York brain implant company announced a partnership with Team Gleason, the ALS charity founded by former New Orleans Saints player Steve Gleason, to give people living with the disease a direct say in how its device is built.
The partnership
The two will set up a structured way for people living with ALS, and the families and caregivers who support them, to give Precision feedback as its brain-computer interface continues in development. They will also run joint education about Precision’s system, Layer 7, for the ALS community and the clinicians who serve it, starting with a shared presence at the American Speech-Language-Hearing Association convention in Indianapolis from 19 to 21 November.
“Experiences like his are why people living with ALS and their caregivers need a real voice in shaping the assistive technology built for them,” Strauss said. “Through this partnership, the ALS community will have a direct say in how we build Layer 7.”
“Precision is building with our community, not just for it, and that is the kind of partnership that changes lives,” said Blair Casey, Team Gleason’s chief executive.
Neither side disclosed financial terms.
Precision’s device
Layer 7 is a thin, flexible film carrying 1,024 electrodes that rests on the surface of the brain without penetrating it. Precision says the film is thin enough to go in through what it calls a micro-slit incision. In March 2025 the FDA cleared a temporary version, Layer 7-T, for use of less than 30 days. Precision is developing its system for people with severe paralysis from conditions such as ALS and traumatic spinal cord injury.
The deal follows one with the spinal cord injury community. In November 2025 Precision partnered with SCI Ventures, a fund backed by the Christopher & Dana Reeve Foundation and other spinal cord injury groups, which made what its managing director called “a seven-figure” investment and gave the company access to its network of patients, doctors and regulatory experts.
Team Gleason’s other implant partner
Team Gleason first partnered with Synchron, whose Stentrode reaches the brain through a blood vessel, in May 2022, feeding its community’s input into that device’s design. The two expanded the partnership in January 2025 to raise awareness of the Synchron BCI Community, a group that keeps people informed about the company’s trials, and Casey was quoted in Synchron’s announcement of its Apple integration in May 2025. With the Precision deal, the charity has now partnered with two implant makers taking different routes to the brain.
Signal: Why it matters
Patient groups are becoming a direct line between brain implant companies and the people their devices are meant for. The venue matters too. Speech-language pathologists are the clinicians who assess people with ALS for communication devices, and Medicare will not pay for a speech-generating device until one has formally evaluated the patient. Precision is also preparing for the question of who pays: in October it hired Katherine Neuenfeldt, who built the market access team at the spinal cord stimulator maker Nevro, as senior vice president of commercial strategies.
Not disclosed
How the feedback will be collected, how many people will take part, and whether Team Gleason will help Precision find participants for future trials.
Forward Radar: What to watch
What Precision and Team Gleason present at the ASHA convention.
Whether Team Gleason helps recruit for the trial of Precision’s permanent implant.
Whether other brain implant makers sign similar agreements with ALS and spinal cord injury groups.
Sources
Primary:
- Team Gleason: Precision Neuroscience and Team Gleason partner to give the ALS community a voice in brain-computer interface development, 13 November 2026
- FDA: 510(k) K242618, Layer 7-T, 30 March 2025
- Precision Neuroscience: Our technology
- Precision Neuroscience via GlobeNewswire: Katherine Neuenfeldt appointed senior vice president, commercial strategies, 15 October 2026
- ASHA Convention 2026, Indianapolis, 19 to 21 November
- CMS Medicare Learning Network: Speech generating devices
- Team Gleason via Business Wire: Team Gleason partners with Synchron, 12 May 2022
- Team Gleason and Synchron via Business Wire: expanded collaboration on the Synchron BCI Community, 6 January 2025
- Synchron via Business Wire: first native BCI integration with iPhone, iPad and Apple Vision Pro, 13 May 2025
Coverage:
- Fierce Medtech: Precision Neuroscience inks partnership with venture fund backed by spinal cord injury advocates, November 2025
- MassDevice: Precision Neuroscience gets backing from SCI Ventures, November 2025
Cross-reference to prior InsideBCI coverage: